GSK Adds 335,000 Shares to Treasury in Ongoing Buyback

GlaxoSmithKline ( (GB:GSK) ) has issued an announcement.

GSK has repurchased 335,000 of its ordinary shares on 2 April 2026 via BNP Paribas under its existing share buyback programme, paying a volume-weighted average price of 2,121.37 pence, with the stock to be held in treasury rather than cancelled. The transaction brings total buybacks since 17 February 2026 to 16,901,521 shares and lifts treasury holdings to 256,792,615 shares, leaving 4,059,387,166 shares in issue and voting rights outstanding, thereby modestly increasing the proportion of capital held in treasury to 6.33% and concentrating ownership for remaining shareholders.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GSK Stock

According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GSK stock, click here.

More about GlaxoSmithKline

GSK plc is a global biopharmaceutical company focused on developing and commercialising medicines and vaccines across multiple therapeutic areas. The group targets large international healthcare markets, with its shares listed in London and frequently held by institutional and retail investors seeking exposure to the pharmaceutical sector.

Average Trading Volume: 9,515,138

Technical Sentiment Signal: Buy

Current Market Cap: £85.69B

For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.